Faculty of Pharmaceutical Sciences, Mahayogi Gorakhnath University, Gorakhpur, 273007, India.
Department of Pharmacology, Delhi Pharmaceutical Sciences and Research University (DPSRU), New Delhi 273007, India; Department of Pharmacy, School of Medical and Allied Sciences, Galgotias University, Greater Noida, India.
Int J Pharm. 2024 Sep 5;662:124403. doi: 10.1016/j.ijpharm.2024.124403. Epub 2024 Jun 27.
Nanotechnology-based drug delivery systems, including siRNA, present an innovative approach to treating breast cancer, which disproportionately affects women. These systems enable personalized and targeted therapies, adept at managing drug resistance and minimizing off-target effects. This review delves into the current landscape of nanotechnology-derived siRNA transport systems for breast cancer treatment, discussing their mechanisms of action, preclinical and clinical research, therapeutic applications, challenges, and future prospects. Emphasis is placed on the importance of targeted delivery and precise gene silencing in improving therapeutic efficacy and patient outcomes. The review addresses specific hurdles such as specificity, biodistribution, immunological reactions, and regulatory approval, offering potential solutions and avenues for future research. SiRNA drug delivery systems hold promise in revolutionizing cancer care and improving patient outcomes, but realizing their full potential necessitates ongoing research, innovation, and collaboration. Understanding the intricacies of siRNA delivery mechanisms is pivotal for designing effective cancer treatments, overcoming challenges, and advancing siRNA-based therapies for various diseases, including cancer. The article provides a comprehensive review of the methods involved in siRNA transport for therapeutic applications, particularly in cancer treatment, elucidating the complex journey of siRNA molecules from extracellular space to intracellular targets. Key mechanisms such as endocytosis, receptor-mediated uptake, and membrane fusion are explored, alongside innovative delivery vehicles and technologies that enhance siRNA delivery efficiency. Moreover, the article discusses challenges and opportunities in the field, including issues related to specificity, biodistribution, immune response, and clinical translation. By comprehending the mechanisms of siRNA delivery, researchers can design and develop more effective siRNA-based therapies for various diseases, including cancer.
基于纳米技术的药物输送系统，包括 siRNA，为治疗乳腺癌提供了一种创新的方法，乳腺癌对女性的影响不成比例。这些系统能够实现个性化和靶向治疗，善于管理药物耐药性并最小化脱靶效应。本综述深入探讨了用于乳腺癌治疗的纳米技术衍生的 siRNA 输送系统的当前现状，讨论了它们的作用机制、临床前和临床研究、治疗应用、挑战和未来前景。强调了靶向输送和精确基因沉默在提高治疗效果和患者预后方面的重要性。本综述针对特异性、生物分布、免疫反应和监管批准等具体障碍，提出了潜在的解决方案和未来研究的途径。siRNA 药物输送系统有望彻底改变癌症治疗并改善患者预后，但要实现其全部潜力，需要持续进行研究、创新和合作。理解 siRNA 输送机制的复杂性对于设计有效的癌症治疗方法、克服挑战以及推进用于各种疾病（包括癌症）的 siRNA 治疗方法至关重要。本文全面综述了用于治疗应用的 siRNA 转运方法，特别是癌症治疗中的方法，阐明了 siRNA 分子从细胞外空间到细胞内靶标的复杂旅程。探讨了内吞作用、受体介导摄取和膜融合等关键机制，以及增强 siRNA 输送效率的创新输送载体和技术。此外，文章还讨论了该领域的挑战和机遇，包括特异性、生物分布、免疫反应和临床转化等相关问题。通过理解 siRNA 输送的机制，研究人员可以设计和开发更有效的基于 siRNA 的治疗方法，用于治疗各种疾病，包括癌症。
